Skip to content GentiBio
  • About
  • Our Team
  • Scientific Approach
    • Engineered Tregs
    • Our Platform
    • Publications
  • Pipeline & Programs
    • Our Pipeline
    • GNTI-122
  • Careers
  • News
  • Contact
GentiBio Mobile Menu Toggle navigation
GentiBio
  • About
  • Our Team
  • Scientific Approach
    • Engineered Tregs
    • Our Platform
    • Publications
  • Pipeline & Programs
    • Our Pipeline
    • GNTI-122
  • Careers
  • News
  • Contact

Genti in the news

  • February 10, 2022

    GentiBio Appoints Industry Veteran Chuck Silberstein as Chief Financial Officer

  • January 14, 2022

    Rapport: To succeed, we must prepare ourselves for failure

  • January 06, 2022

    Biospace: Top Life Sciences Startups to Watch in 2022

  • August 11, 2021

    GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation

  • July 15, 2021

    GentiBio and Forge Biologics Announce Viral Vector Contract Development and GMP Manufacturing Partnership

  • October 28, 2020

    GentiBio Expands Leadership Team and Partnership with MIGAL to Help Advance Development of Engineered Regulatory T Cell Therapies

  • August 05, 2020

    GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases

GentiBio

© 2022 GentiBio

  • Contact
  • Terms and Conditions
  • Privacy Policy
  • Site Credits
  • Twitter
  • LinkedIn